Optimal biological dose: a systematic review in cancer phase I clinical trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimal biological dose: a systematic review in cancer phase I clinical trials
Authors
Keywords
-
Journal
BMC CANCER
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-13
DOI
10.1186/s12885-021-07782-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology
- (2019) Maria-Athina Altzerinakou et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Design considerations for early-phase clinical trials of immune-oncology agents
- (2018) Nolan A. Wages et al. Journal for ImmunoTherapy of Cancer
- Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study
- (2018) Hirokazu Makishima et al. CANCER SCIENCE
- An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials
- (2017) P. Colin et al. Journal of Biopharmaceutical Statistics
- A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
- (2016) David Jamieson et al. EUROPEAN JOURNAL OF CANCER
- A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma
- (2015) Nolan A. Wages et al. Contemporary Clinical Trials
- Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies
- (2015) Diego Tosi et al. JOURNAL OF CLINICAL ONCOLOGY
- CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
- (2015) Philippe A Cassier et al. LANCET ONCOLOGY
- Early phase clinical trials to identify optimal dosing and safety
- (2014) Natalie Cook et al. Molecular Oncology
- Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
- (2013) Sant P Chawla et al. BMC CANCER
- Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
- (2012) Eric Van Den Neste et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
- (2012) Thomas Yau et al. INVESTIGATIONAL NEW DRUGS
- Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial
- (2011) Stephanie E Combs et al. BMC CANCER
- Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies
- (2010) S. Mammoliti et al. ANNALS OF ONCOLOGY
- Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver
- (2010) Sunil K. Geevarghese et al. HUMAN GENE THERAPY
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- (2009) Nadine Houede et al. BIOMETRICS
- Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours
- (2009) Vanesa Gregorc et al. EUROPEAN JOURNAL OF CANCER
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Adaptive designs for selecting drug combinations based on efficacy–toxicity response
- (2007) Vladimir Dragalin et al. JOURNAL OF STATISTICAL PLANNING AND INFERENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started